Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9UNW9
UPID:
NOVA2_HUMAN
Alternative names:
Astrocytic NOVA1-like RNA-binding protein; Neuro-oncological ventral antigen 2
Alternative UPACC:
Q9UNW9; O43267; Q9UEA1
Background:
RNA-binding protein Nova-2, also known as Neuro-oncological ventral antigen 2, plays a pivotal role in the regulation of alternative splicing in neurons. It specifically binds to the sequences 5'-YCAY-3', influencing exon inclusion or exclusion. This protein's unique ability to regulate splicing events of axon guidance related genes is crucial for the development of the central nervous system, affecting neural networks wiring and synapse formation.
Therapeutic significance:
Nova-2 is linked to a neurodevelopmental disorder with or without autistic features and/or structural brain abnormalities, characterized by intellectual disability and motor coordination issues. Understanding the role of RNA-binding protein Nova-2 could open doors to potential therapeutic strategies for these conditions.